The outcomes of the single ascending dose studies in human34,35 are in a manner concordant with observations in preclinical species, even though further studies are needed to fully compare IRPA to currently approved basal insulins and to evaluate its potential for reduced risk of hypoglycemia. Here, INS is linked to Hypoglycemia.